|
🐜
|
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
20 auth.
R. Finn,
S. Qin,
K. Han,
F. Piscaglia,
A. Baron,
Joong-Won Park,
G. Han,
J. Jassem,
J. Blanc,
A. Vogel,
...
D. Komov,
T. J. Evans,
C. Lopez,
C. Dutcus,
M. Guo,
Kenichi Saito,
S. Kraljevic,
T. Tamai,
M. Ren,
A. Cheng
|
11 |
2018 |
11
🐜
|
|
🐜
|
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
31 auth.
P. Jiménez Fonseca,
A. Carmona-Bayonas,
R. Hernández,
A. Custodio,
J. Cano,
A. Lacalle,
I. Echavarría,
I. Macías,
M. Mangas,
L. Visa,
E. Buxó,
Felipe Álvarez Manceñido,
A. Viúdez,
C. Pericay,
A. Azkárate,
...
A. Ramchandani,
C. Lopez,
E. Martínez de Castro,
A. Fernández Montes,
F. Longo,
R. Sánchez Bayona,
M. Limón,
A. Díaz‐Serrano,
Alfonso Martín Carnicero,
D. Arias,
P. Cerda,
F. Rivera,
J. Viéitez,
M. Sánchez Cánovas,
M. Garrido,
J. Gallego
|
6 |
2017 |
6
🐜
|
|
🐜
|
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
21 auth.
Barbara Nuñez-Valdovinos,
A. Carmona-Bayonas,
P. Jiménez-Fonseca,
J. Capdevila,
Á. Castaño-Pascual,
M. Benavent,
Jose Javier Pi Barrio,
A. Teule,
V. Alonso,
A. Custodio,
...
M. Marazuela,
A. Segura,
A. Beguiristain,
M. Llanos,
María Purificación Martínez del Prado,
J. Díaz-Pérez,
D. Castellano,
I. Sevilla,
C. Lopez,
T. Alonso,
R. García-Carbonero
|
6 |
2018 |
6
🐜
|
|
🐜
|
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
17 auth.
A. Vogel,
S. Qin,
M. Kudo,
Yun Su,
S. Hudgens,
T. Yamashita,
Jung‐Hwan Yoon,
L. Fartoux,
K. Simon,
C. Lopez,
...
M. Sung,
K. Mody,
Tatsuroh Ohtsuka,
T. Tamai,
L. Bennett,
G. Meier,
V. Breder
|
6 |
2021 |
6
🐜
|
|
🐜
|
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.
20 auth.
Miguel J. Sotelo,
Javier Sastre,
M. Maestro,
S. Veganzones,
J. Viéitez,
V. Alonso,
C. Grávalos,
Pilar Escudero,
Ruth Vera,
Enrique Aranda,
...
P. García-Alfonso,
J. Gallego-Plazas,
C. Lopez,
C. Pericay,
A. Arriví,
P. Vicente,
P. Ballesteros,
E. Élez,
A. López-Ladrón,
E. Díaz-Rubio
|
6 |
2015 |
6
🐜
|
|
🐜
|
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
29 auth.
J. Capdevila,
N. Fazio,
C. Lopez,
A. Teule,
J. Valle,
S. Tafuto,
A. Custodio,
N. Reed,
M. Raderer,
E. Grande,
R. García-Carbonero,
P. Jiménez-Fonseca,
J. Hernando,
Alberto Bongiovanni,
F. Spada,
...
V. Alonso,
L. Antonuzzo,
A. Spallanzani,
A. Berruti,
A. La Casta,
I. Sevilla,
P. Kump,
D. Giuffrida,
X. Merino,
L. Trejo,
P. Gajate,
I. Matos,
A. Lamarca,
T. Ibrahim
|
5 |
2021 |
5
🐜
|
|
🐜
|
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
29 auth.
A. Carmona-Bayonas,
P. Jiménez-Fonseca,
A. Lamarca,
J. Barriuso,
A. Castaño,
M. Benavent,
V. Alonso,
M. Riesco-Martinez,
T. Alonso-Gordoa,
A. Custodio,
M. Sánchez Cánovas,
Jorge Hernando Cubero,
C. Lopez,
A. Lacasta,
A. Fernández Montes,
...
M. Marazuela,
G. Crespo,
P. Escudero,
J. Díaz,
E. Feliciangeli,
J. Gallego,
M. Llanos,
A. Segura,
F. Vilardell,
J. C. Percovich,
E. Grande,
J. Capdevila,
J. Valle,
R. García-Carbonero
|
5 |
2019 |
5
🐜
|
|
🐜
|
Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
29 auth.
A. Custodio,
A. Carmona-Bayonas,
P. Jiménez-Fonseca,
M. Sanchez,
A. Viúdez,
R. Hernández,
J. Cano,
I. Echavarría,
C. Pericay,
M. Mangas,
L. Visa,
E. Buxó,
T. García,
A. Palomo,
F. A. Manceñido,
...
A. Lacalle,
I. Macías,
A. Azkárate,
A. Ramchandani,
A. Montes,
C. Lopez,
F. Longo,
R. S. Bayona,
M. Limón,
A. Díaz‐Serrano,
A. Hurtado,
R. Madero,
C. Gómez,
J. Gallego
|
5 |
2017 |
5
🐜
|
|
🐜
|
Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).
20 auth.
M. Kudo,
R. Finn,
S. Qin,
K. Han,
K. Ikeda,
A. Cheng,
F. Piscaglia,
K. Ueshima,
H. Aikata,
A. Vogel,
...
C. Lopez,
M. Pracht,
Z. Meng,
B. Daniele,
Joong-Won Park,
D. Palmer,
C. Dutcus,
T. Tamai,
Kenichi Saito,
R. Lencioni
|
5 |
2019 |
5
🐜
|
|
🐜
|
1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
20 auth.
J. Capdevila,
A. Teule,
C. Lopez,
R. García-Carbonero,
M. Benavent,
A. Custodio,
A. Cubillo,
V. Alonso,
T. A. Gordoa,
A. Carmona-Bayonas,
...
G. Crespo,
M. Blanco-Codesido,
P. Jiménez-Fonseca,
A. Viúdez,
A. L. Muñoa,
I. Sevilla,
M. Llanos,
A. Segura,
Jorge Hernando-Cubero,
J. Manzano
|
5 |
2020 |
5
🐜
|
|
🐜
|
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features
18 auth.
R. Salazar,
J. Capdevila,
B. Laquente,
J. Manzano,
C. Pericay,
M. M. Villacampa,
C. Lopez,
F. Losa,
M. Safont,
A. Gómez,
...
V. Alonso,
P. Escudero,
J. Gallego,
J. Sastre,
C. Grávalos,
S. Biondo,
A. Palacios,
E. Aranda
|
5 |
2015 |
5
🐜
|
|
🐜
|
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
18 auth.
F. Rivera,
M. Izquierdo-Manuel,
P. García-Alfonso,
E. Martínez de Castro,
J. Gallego,
M. Limón,
M. Alsina,
L. López,
M. Galán,
E. Falcó,
...
J. Manzano,
E. González,
N. Muñoz-Unceta,
C. Lopez,
E. Aranda,
E. Fernández,
M. Jorge,
P. Jiménez-Fonseca
|
5 |
2021 |
5
🐜
|
